Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy-Reference-Cited by-同舟云学术

Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy

Published:2024-05 Issue: Volume:74 Page:101068
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Zhang Binglei,Shi Jianxiang,Shi Xiaojing,Xu Xiaolu,Gao Le,Li Song,Liu Mengmeng,Gao Mengya,Jin Shuiling,Zhou Jian,Fan Dandan,Wang Fang,Ji Zhenyu,Bian Zhilei,Song Yongping,Tian Wenzhi,Zheng Yichao,Xu Linping,Li Wei

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference72 articles.

1. CD47 blockade by Hu5F9-G4 and rituximab in Non-Hodgkin’s lymphoma;Advani;N. Engl. J. Med.,2018

2. Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results;Advani;J. Clin. Oncol.,2018

3. A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies;Ansell;Blood,2016

4. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies;Ansell;Clin. Cancer Res.,2021

5. A vaccine targeting resistant tumours by dual T cell plus NK cell attack;Badrinath;Nature,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of bioassay platforms for biopharmaceuticals using Jurkat-CAR cells by AICD;Journal of Pharmaceutical and Biomedical Analysis;2024-12

2. Construction and preclinical evaluation of a 124I-labelled bispecific antibody targeting PD-L1 and PD-L2;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-19

3. Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: How to Convert “Cold” Tumors to “Hot” Tumors;International Journal of Molecular Sciences;2024-06-29

4. Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives;Frontiers in Immunology;2024-05-22

5. The advances in targeting CD47/SIRPα “do not eat me” axis and their ongoing challenges as an anticancer therapy;Oncotarget;2024-01-06